-New Collaboration Brings ZyGEM's Unique Temperature-Controlled DNA Extraction Technology to Advalytix Customers as Private-Label Kits-
SOLANA BEACH, Calif. and HAMILTON, New Zealand and MUNICH, Germany, Oct. 16 /PRNewswire/ -- ZyGEM Corp. Ltd. today announced that it has entered into an agreement with the Advalytix product team of Olympus Life Science Research Europa GmbH to produce a private-label line of DNA extraction products. The collaboration will combine ZyGEM's advanced enzymatic nucleic acid extraction technology and Advalytix's expertise in single-cell molecular tests for life science research and diagnostic applications.
ZyGEM's DNA extraction technology uses a proprietary thermophilic enzyme to extract DNA from samples using a single closed-tube system. ZyGEM's approach simplifies laboratory workflow, minimises error, reduces the risk of contamination and ensures sample integrity, while also reducing costs. The technology can be specifically formulated for use with a wide range of different sample types without the need for further purification. ZyGEM's technology has been validated for use in research, forensic, diagnostic, agriculture and animal health applications.
"ZyGEM's unique temperature-controlled DNA extraction technology provides important advantages that are especially relevant as demand for DNA analysis continues to increase, and we are delighted to partner with an innovative group such as Advalytix to make our technology available to more users," said Paul Kinnon, CEO of ZyGEM. "This new agreement for private-label DNA extraction products is the most recent in a series of ZyGEM collaborations with diverse partners to ensure wide availability of our versatile technology, and we look forward to a mutually productive relationship with Advalytix."
Advalytix will market private-label DNA extraction products based on ZyGEM's temperature-controlled extraction (TEC) technology. The kits are designed to work with Advalytix's single-cell molecular diagnostics and its miniaturised diagnostic and biological tests for research and development. Advalytix is Olympus' division focusing on cell-based molecular biology. Advalytix's products uniquely link imaging technologies such as microscopy with nucleic acid analysis, enabling fully integrated solutions with optimised instruments and reagents.
"We are committed to providing our customers with innovative technology that enables them to conduct analyses and experiments more simply, rapidly, accurately and cost effectively, and we believe that access to ZyGEM's distinctive temperature-controlled nucleic acid extraction technology will help advance that goal," said Frank Feist, executive director of the Advalytix business, Olympus America. "We look forward to offering private-label DNA extraction products based on the ZyGEM technology to our growing customer base."
Terms of the agreement were not disclosed.
About ZyGEM Corporation
ZyGEM Corporation Limited is a rapidly growing biotechnology company with a range of innovative enzyme-based products and technologies based on the company's exclusive collection of microorganisms from extreme environments. ZyGEM's technology has significant competitive advantages over existing methods and has potential applications in a number of sizeable global markets. ZyGEM currently produces DNA extraction and detection products, molecular biology enzymes and individual enzymes and diagnostics, serving life sciences customers in basic research, forensics, clinical diagnostics and agriculture. ZyGEM has facilities in New Zealand and the U.S.A. For more information, visit http://www.ZyGEM.com
Advalytix is Olympus' worldwide competence centre for cell-based
molecular biology, with a focus on single-cell molecular diagnostics and
the miniaturisation of diagnostic and biological tests for research and
development. Advalytix products uniquely link imaging technologies such as
microscopy with nucleic acid analysis, enabling turnkey solutions with
optimised instruments and reagents.
Corporate: Media: Corporate/Media:
Paul Kinnon Barbara Lindheim Frank Feist
President and CEO BioCom Partners Executive Director Advalytix
858-720-8333 212-918-4650 (987)405-2533
|SOURCE ZyGEM Corporation|
Copyright©2008 PR Newswire.
All rights reserved